ITGB6 as a Radioligand Therapy Target
ITGB6, integrin subunit beta 6, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, ITGB6 staining is highest in cervical cancer (100% of samples positive), bladder cancer (67% of samples positive) and skin cancer (83% of samples positive). Clinical status: Clinical-stage (up to phase 3, any modality).
Is ITGB6 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in cervical cancer, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ✅ Clinical precedent: Clinical-stage (up to phase 3, any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
ITGB6 expression in cancer
Protein expression of ITGB6 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Cervical Cancer | 0.64 | High | 100% |
| Bladder Cancer | 0.53 | High | 67% |
| Skin Cancer | 0.47 | Medium | 83% |
| Lung Cancer | 0.47 | Medium | 83% |
| Neuroendocrine Tumors | 0.42 | Medium | 100% |
| Pancreatic Cancer | 0.37 | Medium | 70% |
| Head and Neck Cancer | 0.33 | Medium | 75% |
| Endometrial Cancer | 0.24 | Medium | 46% |
| Ovarian Cancer | 0.21 | Medium | 46% |
| Breast Cancer | 0.19 | Low | 25% |
| Colorectal Cancer | 0.17 | Low | 50% |
| Gastric Cancer | 0.10 | Low | 20% |
| Testicular Cancer | 0.07 | Low | 20% |
| Kidney Cancer | 0.03 | Low | 8% |
| Liver Cancer | 0.03 | Low | 8% |
Not detected by IHC in: lymphoma, melanoma, thyroid cancer, prostate cancer, glioma.
Is ITGB6 internalized?
Nuclens has not yet extracted internalization evidence for ITGB6. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
ITGB6 clinical trials
Clinical-stage (up to phase 3, any modality). Nuclens hasn't indexed trials for ITGB6 yet. Search ClinicalTrials.gov for ITGB6 trials.
ITGB6 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ITGB6 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
ITGB6 gene essentiality (DepMap)
CRISPR knockout effect across 1256 cancer cell lines: -0.03 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related cervical cancer radioligand targets
c-MET (MET) · EGFR · HER3 (ERBB3) · CEA (CEACAM5) · SSTR2 · Mesothelin (MSLN) · STEAP2 · FAP
See all radioligand therapy targets in cervical cancer.
See how ITGB6 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.